ATyr Pharma Inc (ATYR)

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing product candidates based on tRNA synthetase biology for potential applications in fibrosis and inflammation. Its lead candidate, efzofitimod, is a selective NRP2 modulator being evaluated in Phase 3 for pulmonary sarcoidosis and in Phase 2 studies for sarcoidosis and systemic sclerosis-associated interstitial lung disease. The program is also being studied in other ILDs, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. The company’s pipeline also includes ATYR0101, a preclinical fusion protein derived from aspartyl-tRNA synthetase for fibrosis, and ATYR0750, a domain of alanyl-tRNA synthetase being developed for liver disorders. aTyr Pharma has a collaboration and license agreement with Kyorin Pharmaceutical for efzofitimod development and commercialization in ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.